4-肼-2,6-二甲基嘧啶 | 14331-56-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-肼-2,6-二甲基嘧啶
• 英文名称: 4-hydrazinyl-2,6-dimethylpyrimidine
• 英文别名: 4-Hydrazino-2,6-dimethylpyrimidine；(2,6-dimethylpyrimidin-4-yl)hydrazine
• CAS: 14331-56-7
• 化学式: C₆H₁₀N₄
• mdl: MFCD00102150
• 分子量: 138.172
• InChiKey: HVAYIAWJHRUOBC-UHFFFAOYSA-N

物化性质

• 熔点：
  182-184°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090

SDS

Name:	4-Hydrazino-2 6-dimethylpyrimidine 95+% Material Safety Data Sheet
Synonym:
CAS:	14331-56-7

Section 1 - Chemical Product MSDS Name:4-Hydrazino-2 6-dimethylpyrimidine 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14331-56-7	4-Hydrazino-2,6-dimethylpyrimidine	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 14331-56-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 182 - 184 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H10N4
Molecular Weight: 138

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14331-56-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Hydrazino-2,6-dimethylpyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 14331-56-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 14331-56-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 14331-56-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-肼-2,6-二甲基嘧啶 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3-(2-thienyl)-1-(2,6-dimethylpyrimidin-4-yl)pyrazole-4-carboxaldehyde
  参考文献：
  名称：

  Synthesis and antibacterial evaluation of some new 4-substituted-3-aryl-1-(2,6-dimethylpyrimidin-4-yl)pyrazoles

  摘要：

  AbstractSynthesis of a series of new 4‐substituted‐3‐aryl‐1‐(2,6‐dimethylpyrimidin‐4‐yl)pyrazoles (2a, 2b, 2c, 2d, 2e, 2f, 2g, 3a, 3b, 3c, 3d, 3e, 3f, 3g, and 4a, 4b, 4c, 4d, 4e, 4f, 4g) is described. All the synthesized compounds were evaluated in vitro for their antibacterial activity against two gram‐positive and two gram‐negative bacteria, namely, Bacillus subtilis (MTCC 8509), Bacillus stearothermophilus (MTCC 8508), Escherichia coli (MTCC 51), and Pseudomonas putida (MTCC 121), and their activity was compared with two commercial antibiotics, streptomycin and chloramphenicol. Two compounds, namely, 3‐(4‐anisyl)‐1‐(2,6‐dimethylpyrimidin‐4‐yl)pyrazole‐4‐carboxaldehyde (2b) and 3‐(2‐thienyl)‐1‐(2,6‐dimethyl pyrimidin‐4‐yl)pyrazole‐4‐carboxaldehyde (2g) were found to be equipotent to streptomycin and chloramphenicol against gram‐negative bacteria, E. coli having minimum inhibitory concentration (MIC) value = 4 μg/mL. Compounds 4b and 4d also displayed good activity against E. coli with MIC = 8 μg/mL. J. Heterocyclic Chem., (2011).

  DOI：

  10.1002/jhet.701
• 作为产物：
  描述：

  2-氨基-4-氯-6-甲基嘧啶 在 一水合肼 作用下， 生成 4-肼-2,6-二甲基嘧啶
  参考文献：
  名称：

  Claesen; Vanderhaeghe, Bulletin des Societes Chimiques Belges, 1959, vol. 68, p. 30,55

  摘要：

  DOI：

文献信息

• [EN] FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS<br/>[FR] DERIVES HETEROARYL FUSIONNES A UTILISER EN TANT QU'INHIBITEURS DE LA KINASE P38
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005073189A1

  公开（公告）日：2005-08-11

  Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

  化合物的化学式（I）是p38激酶的抑制剂，并且在治疗由p38激酶活性介导或由p38活性产生的细胞因子介导的疾病状态或疾病状态中有用。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020097609A1

  公开（公告）日：2020-05-14

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的失调的方法。这些化合物具有Formula（X）的结构或其在药学上可接受的异构体，消旋体，水合物，溶剂合物，同位素或盐，其中R1，R2，R3，R4，R9，R10，R11和R12，Q5，Q6，Q7和Q8如本文所定义。
• [EN] HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRANSPORT NUCLÉAIRE CONTENANT DE L'HYDRAZIDE ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2013019548A1

  公开（公告）日：2013-02-07

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  这项发明通常与核运输调节剂有关，例如CRM1抑制剂，更具体地涉及一种由结构式(I)表示的化合物，或其药学上可接受的盐，其中变量的值和备选值如本文所定义和描述。该发明还包括合成和使用结构式I的化合物，或其药学上可接受的盐或组合物，例如在与CRM1活性相关的生理状况的治疗、调节和/或预防中的应用。
• Organoiodine (III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents
  作者：Ravi Kumar、Reshmi R. Nair、Saurabh Sudha Dhiman、Jitender Sharma、Om Prakash

  DOI：10.1016/j.ejmech.2008.06.004

  日期：2009.5

  Synthesis of 12 new 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines (3a–l) has been accomplished by the oxidation of pyrimidinylhydrazones (2a–l) of various aryl/heteroaryl aldehydes using 1.1 equiv. of iodobenzene diacetate (IBD) in dichloromethane. All the compounds 3a–l tested in vitro for their antibacterial activity against two Gram-positive bacteria namely, Bacillus subtilis,

  12种新的3-芳基/杂芳基-5,7-二甲基-1,2,4-三唑并[4,3- c ]嘧啶（3a - l）的合成已通过氧化亚氨基的嘧啶基hydr（2a - l）来完成。使用1.1当量的各种芳基/杂芳基醛 二氯甲烷中的二碘代碘苯（IBD）。所有化合物3a – l在体外均测试了对两种革兰氏阳性菌即枯草芽孢杆菌，嗜热脂肪芽孢杆菌和两种革兰氏阴性菌恶臭假单胞菌，大肠杆菌的抗菌活性。。两种化合物，即3-（2,4-二氯苯基）-5,7-二甲基-1,2,4-三唑并[4,3- c ]嘧啶（3j）和3-（4-羟基-2-甲氧基苯基）发现-5,7-二甲基-1,2,4-三唑并[4,3- c ]嘧啶（3l）比市售抗生素（氯霉素和链霉素）具有同等效力或更强效。